Medical Genetics | Endocrinology | Endocrine & Metabolic Pharmacology | Thyroid | Head & Neck Disorders
The TRHR gene is associated to hypothalamo-pituitary sensitivity to levothyroxine in thyroidectomized patients
Giulia Brigante*, Giorgia Spaggiari, Katia Cioni, Valentina Gnarini, Elisa Pignatti, Livio Casarini, Marco Marino, Frank Tuettelmann, Cesare Carani, Manuela Simoni
*Corresponding author: Giulia Brigante
Department of Medicine, Endocrinology, Metabolisms and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy
Azienda Unità Sanitaria Locale di Modena (AUSL), Modena, Italy
F1000Posters 2012, 3: 777 (poster) [English]
Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology (ICE/ECE) 2012, 5 - 9 May 2012, 1755
Patients thyroidectomized for thyroid cancer need variable doses of levothyroxine (LT4) to obtain thyroid stimulating hormone (TSH) suppression. A predetermined thyroid function set-point for each individual has been hypothesized, suggesting a genetic influence in the regulation of pituitary-thyroid axis. We hypothesized that genetic variants of the TRHR gene could be associated with a different hypothalamo-pituitary sensitivity to the negative feedback of the thyroid hormones.
We demonstrated an association between TSH and discrete alleles of the TRHR gene identified by the markers SNPs rs3134105 and rs3110040 in totally thyroidectomized patients with diagnosis of thyroid cancer under subsuppressive LT4 therapy. The TRHR gene is a determinant of hypothalamo-pituitary sensitivity to levothyroxine in such patients.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License